Endoscopic Ultrasound Determines Disease Activity in Crohn's Disease And Ulcerative Colitis
NCT03863886
Recruiting
Although Crohn's disease and ulcerative colitis are the main subtypes of inflammatory bowel disease, they differ substantially in disease behavior, prognosis, and treatment paradigm. However, making an accurate diagnosis of Crohn's disease versus ulcerative colitis and assessing disease activity beyond the level of mucosal inflammation remain challenging with contemporary modalities. The objective of the study is to determine the novel role of endoscopic ultrasound in A) differentiating Crohn's... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/27/2021
Locations: Carilion Clinic, Roanoke, Virginia
Conditions: Crohn Disease, Ulcerative Colitis
Register for Updates
Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis
NCT04987307
Recruiting
The main purpose of this study is to evaluate the effect of efavaleukin alfa on induction of clinical remission in participants with moderately to severely active ulcerative colitis (UC). Participants will be randomized to receive 1 of 3 efavaleukin alfa doses or placebo during a 12-week induction period. Participants who complete the 12-week induction period will have the option to enter an exploratory long-term treatment period for up to 40 weeks (total of up to 52 weeks of treatment) if, in... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
11/29/2023
Locations: Digestive Health Specialists of the Southeast, Dothan, Alabama +187 locations
Conditions: Ulcerative Colitis
Register for Updates
Long-term Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05672199
Recruiting
The primary objective of this study is to evaluate the long-term safety and tolerability of efavaleukin alfa in participants with moderate to severe ulcerative colitis (UC).
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
11/29/2023
Locations: Santa Maria Gastroenterology Medical Group, Santa Maria, California +15 locations
Conditions: Ulcerative Colitis
Register for Updates
CP101 for the Treatment of Ulcerative Colitis
NCT05852574
Recruiting
This is a dose ranging exploratory phase 1 pilot study to assess engraftment, safety, and efficacy of CP101, an oral microbiome therapeutic, in participants with active mild-to-moderate Ulcerative colitis. A total of 30 patients who meet eligibility criteria will be randomized 1:1 to either a short or extended induction dosing with CP101. An assessment of the microbiome will occur at baseline, Day 6, Week 4, Week 8, Week 12, Week 16, and Week 24.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/27/2023
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Ulcerative Colitis
Register for Updates
Evaluation of SPH3127 in Patients With Mild-to-Moderate Ulcerative Colitis
NCT05019742
Recruiting
SPH3127-US-01 is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics, and preliminary efficacy of SPH3127 for the treatment of mild-to-moderate ulcerative colitis.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
11/24/2023
Locations: Clinical Research Associates, LLC, Huntsville, Alabama +15 locations
Conditions: Ulcerative Colitis
Register for Updates
Immune Regulation in Ulcerative Colitis or Crohn s Disease
NCT00001184
Recruiting
This study will investigate in patients with Crohn s disease and ulcerative colitis how the body s immune system controls inflammation in the gastrointestinal tract (stomach and intestines)-specifically, how lymphocytes (a type of white blood cell) function in inflammatory responses. This protocol does not involve any experimental treatments. Patients between the ages of 0 and 75 years of age with Crohn s disease or ulcerative colitis or symptoms of inflammatory bowel disease may be eligible fo... Read More
Gender:
All
Ages:
75 years and below
Trial Updated:
11/23/2023
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Inflammatory Bowel Disease, Ulcerative Colitis, Chrohn's Disease
Register for Updates
A Study to Evaluate Efficacy and Safety of MK-7240 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
NCT06052059
Recruiting
The purpose of this protocol is to evaluate the efficacy and safety of MK-7240 in participants with moderately to severely active ulcerative colitis. Study 1's primary hypotheses are that at least 1 MK-7240 dose level is superior to Placebo in the proportion of participants achieving clinical remission per Modified Mayo Score at Week 12, and that at least 1 MK-7240 dose level is superior to Placebo in the proportion of participants achieving clinical remission per Modified Mayo Score at week 52.... Read More
Gender:
All
Ages:
Between 16 years and 75 years
Trial Updated:
11/22/2023
Locations: Digestive Health Specialists ( Site 0135), Dothan, Alabama +14 locations
Conditions: Ulcerative Colitis
Register for Updates
Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis
NCT04624230
Recruiting
This study, A3921210 is designed to evaluate the efficacy, safety and pharmacokinetics (PK) of tofacitinib in pediatric participants with moderately to severely active UC. In the US and EU, patients with prior TNFi failure or intolerance will be enrolled. Outside of the US or EU, patients having had inadequate response or intolerance to oral or IV corticosteroids or azathioprine or 6-mercaptopurine or TNFi will be enrolled. All eligible participants will initially receive open label tofacitinib... Read More
Gender:
All
Ages:
Between 2 years and 17 years
Trial Updated:
11/21/2023
Locations: Phoenix Children's Hospital, Phoenix, Arizona +96 locations
Conditions: Ulcerative Colitis
Register for Updates
Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.
NCT05782907
Recruiting
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). This study will assess how safe and effective Upadacitinib is in treating pediatric participants with UC. Adverse events and change in disease activity will be assessed. Upadacitinib (RINVOQ) is a drug approved in adults for moderate- to severely active UC and is being developed for moderate- to severely active UC in pediatric participa... Read More
Gender:
All
Ages:
Between 2 years and 17 years
Trial Updated:
11/21/2023
Locations: Phoenix Children's Hospital /ID# 250135, Phoenix, Arizona +10 locations
Conditions: Ulcerative Colitis
Register for Updates
A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative Colitis
NCT05549323
Recruiting
This is a study to learn if the experimental medicine (called PF-07054894) is safe, effective, and how it is processed in adult people with ulcers in the colon.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
11/16/2023
Locations: IHS Health Research, Kissimmee, Florida +25 locations
Conditions: Ulcerative Colitis
Register for Updates
Chronotherapy of 5-Aminosalicylic Acid in Ulcerative Colitis
NCT05213234
Recruiting
The hypothesis of this study is that appropriate time of day of administration of oral, once daily 5-ASA therapy in alignment with the host circadian rhythms will improve subclinical inflammation and microbial structure/function and increase mucosal 5-ASA levels. All subjects will be randomized to once daily 5-ASA medications at two different times of the day: between 06:00 - 10:00 h or 18:00 - 22:00 h. Three disease assessments will performed at: 1) enrollment just before randomization; 2) mon... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
11/16/2023
Locations: Rush University Medical Center, Chicago, Illinois +1 locations
Conditions: Ulcerative Colitis
Register for Updates
VE202 in Patients With Mild-to-Moderate Ulcerative Colitis
NCT05370885
Recruiting
A Phase 2 study to evaluate the safety, efficacy, and microbiota changes of VE202 in patients with mild to moderate ulcerative colitis (UC).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
11/14/2023
Locations: Digestive Health Specialists, Dothan, Alabama +30 locations
Conditions: Ulcerative Colitis, Colitis, Ulcerative
Register for Updates